Cargando…
Chinese Herbal Medicines Might Improve the Long-Term Clinical Outcomes in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: Results of a Decision-Analytic Markov Model
Aims. The priority of Chinese herbal medicines (CHMs) plus conventional treatment over conventional treatment alone for acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) was documented in the 5C trial (chictr.org number: ChiCTR-TRC-07000021). The study was designed to eval...
Autores principales: | Wang, Shao-Li, Wang, Cheng-Long, Wang, Pei-Li, Xu, Hao, Chen, Ke-Ji, Shi, Da-Zhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606398/ https://www.ncbi.nlm.nih.gov/pubmed/26495019 http://dx.doi.org/10.1155/2015/639267 |
Ejemplares similares
-
Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
por: Zheng, Guo-Hua, et al.
Publicado: (2012) -
Optimizing Prescription of Chinese Herbal Medicine for Unstable Angina Based on Partially Observable Markov Decision Process
por: Feng, Yan, et al.
Publicado: (2013) -
Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study
por: Wang, Shao-Li, et al.
Publicado: (2013) -
Holistic Regulation of Angiogenesis with Chinese Herbal Medicines as a New Option for Coronary Artery Disease
por: Yuan, Rong, et al.
Publicado: (2018) -
Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
por: Iwasaki, Kohichiro, et al.
Publicado: (2009)